Clinical Trial Update: Study of KYV-101 Anti-CD19 CAR T Therapy in Adult Dermatomyositis [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating KYV-101, an anti-CD19 CAR T therapy, in adults with dermatomyositis is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dermatomyositis

Drugs mentioned

• KYV-101

Snippet

Sponsor: Stanford University | Conditions: Dermatomyositis | Phase 1 | Status: RECRUITING